This may be explained by somatic second-hits that are not identifiable within the limits of the genetic testing methodologies used, such that PAM may still act as a tumour suppressor like other genes involved in pituitary tumorigenesis, such as MEN1 and AIP (2). Here, AIP is linked to neoplasm.